Pharmacologic study of cremophor el in cancer patients with impaired hepatic function receiving paclitaxel

Journal of Oncology Pharmacy Practice

Volumn 5, Issue 2, 1999, Pages 83-86

  Panday, Nannan Vinodh R ^a,b   Huizing, Manon T ^b   Tellingen Van, Olaf ^b   Hakvoort, Robert A ^b   Willemse, Pax H B ^c   Graeff De, Alexander ^d   Vermorken, Jan B ^e   Beijnen, Jos H ^a,b,f  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Academic Hospital Utrecht   (Netherlands)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cremophor EL; Liver function; Paclitaxel; Pharmacokinetics

Indexed keywords

EID: 0009706939     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529900500204     Document Type: Article

References (21)

1. Wani MC, Taylor HL, Wall ME. Plant antitumor agents: The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.J Am Chem Soc. 1971;93:2325-2327.
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665-667.
3. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res.1996;2:1843-1849.
4. Rowinsky EK, Donehower RC. Paclitaxel. N Engl J Med. 1995;332: 1004-1014.
5. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-1268.
6. Nannan Panday VR, Huizing MT, Ten Bokkel Huinink WW, et al. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest. 1997;14:418-427.
7. Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol. 1993;11:2127-2135.
8. Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994;12:532-538.
9. Gianni L, Kearns CM, Gianni A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmaco-dynamic relationships in humans. J Clin Oncol. 1995;13:180-190.
10. Sparreboom A, Van Tellingen O, Nooijen WJ, et al. Nonlinear murine pharmacokinetics of paclitaxel results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56:2112-2115.
11. Nygren P, Csóka K, Jonsson B, et al. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br J Cancer. 1995;71:478-481.
12. Schuurhuis GJ, Broxterman HJ, Pinedo HM, et al. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer. 1990;62:591-594.
13. Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer. 1992;66:62-68.
14. Webster L, Linsenmeyer M, Millward M, et al. Measurement of Cremophor EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst. 1993;85:1685-1690.
15. Van Tellingen O, Sparreboom A, Huizing MT, et al. The analysis and preliminary pharmacokinetics of Cremophor EL (CrEL) in human plasma. Proc Am Soc Clin Oncol. 1996;15:479-479.
16. Rischin D, Webster LK, Millward MJ, et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst. 1996;88:1297-1301.
17. Roman ID, Monte MJ, Esteller A, et al. Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL. Transplantation. 1989;48:554-558.
18. Chan FK, Shaffer EA. Cholestatic effects of cyclosporin in the rat. Transplantation. 1997;63:1574-1578.
19. Nannan Panday VR, Huizing MT, Willemse PHB, et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol. 1997;24(suppl 11):S11-34-S11-38.
20. Huizing MT, Rosing H, Vermorken JB, et al. Pharmacology of paclitaxel (P) and metabolites in patients with altered liver function. Eur J Cancer. 1995;31A(suppl 5):S192-S192.
21. Sparreboom A, Van Tellingen O, Huizing MT, et al. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996;681:355-362.